Cite
HARVARD Citation
Hapgood, G. et al. (2019). A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma. Leukemia & lymphoma. 60 (4), pp. 904-911. [Online].